6004 ORAL Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial

S.Novick; S.OBrien; J.Moore; T.Boyd; L.Ding; K.Rai

首页> 外文期刊>European Journal of Cancer Supplements >6004 ORAL Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial

【24h】

6004 ORAL Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial

机译：6004 ORAL Oblimersen联合氟达拉滨/环磷酰胺（FC）显着提高了慢性难治性白血病（CLL）复发非难治性患者（Pts）的完全缓解和总体生存：一项前瞻性随机3期试验的结果

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
S.Novick; S.OBrien; J.Moore; T.Boyd; L.Ding; K.Rai;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. 6004 ORAL Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial [J] . S.Novick, S.OBrien, J.Moore, European Journal of Cancer Supplements . 2007,第4期

机译：6004 ORAL Oblimersen联合氟达拉滨/环磷酰胺（FC）显着提高了慢性难治性白血病（CLL）复发非难治性患者（Pts）的完全缓解和总体生存：一项前瞻性随机3期试验的结果
2. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. [J] . OBrien S, Moore JO, Boyd TE Journal of Clinical Oncology . 2009,第31期

机译：氟达拉滨联合环磷酰胺加或不加奥利本的一项随机III期临床试验，对复发性或难治性慢性淋巴细胞性白血病患者的5年生存期。
3. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. [J] . OBrien S, Moore JO, Boyd TE, Journal of Clinical Oncology . 2007,第9期

机译：氟达拉滨联合环磷酰胺加或不加奥利马森钠（Bcl-2反义）在复发或难治性慢性淋巴细胞性白血病患者中的III期随机试验。
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen [O] . Susan OBrien, Joseph O. Moore, Thomas E. Boyd, -1

机译：氟达拉滨加环磷酰胺加或不加奥利本的随机III期复发或难治性慢性淋巴细胞性白血病患者的5年生存率
6. Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. [O] . Howard DR, Munir T, McParland L, 2017

机译：临床效果和成本效益结果来自以前未治疗的慢性淋巴细胞白血病患者的随机IIB期试验，比较氟达拉滨，环磷酰胺和利妥昔单抗与氟达拉滨，环磷酰胺，米托蒽醌和低剂量利妥昔单抗：减毒剂量利妥昔单抗与化疗治疗慢性淋巴细胞白血病（aRCTIC）审判。

6004 ORAL Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial

著录项

引文网络

相似文献

相关主题

期刊订阅